Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin Therapy (HER 2)
|ClinicalTrials.gov Identifier: NCT00530569|
Recruitment Status : Unknown
Verified January 2012 by AHS Cancer Control Alberta.
Recruitment status was: Active, not recruiting
First Posted : September 17, 2007
Last Update Posted : January 28, 2013
|Condition or disease||Intervention/treatment|
|Breast Cancer||Procedure: Blood Test|
- Single Variate analysis will be performed to correlate variables such as tumour size, grade, stage, ER status, PR status and biopsy HER2 status with soluble HER2 levels.
- Soluble HER2 levels will be analyzed as both a continuous and categorized variable.
- The analysis will attempt to discern the relationship between soluble HER2 levels, HER2 positive circulating epithelial cell level and treatment response.
- This will provide evidence of the effect various treatments have on HER2 levels. HER2 levels both in patients treated with Herceptin and those on other treatment protocols, will be related to clinical disease measures such as time to progression, time to failure, duration of response and duration of survival.
- An initial model of the relationship between these factors and soluble HER2 as a marker will be established from the data.
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin Therapy|
|Study Start Date :||August 2007|
Procedure: Blood Test
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00530569
|Tom Baker Cancer Centre|
|Calgary, Alberta, Canada, T2N 4N2|
|Principal Investigator:||Bill Kangerloo, M.D.||Alberta Health Services|